SURPASS trial programme: difference between revisions
Diff·revision 20 → 21·00:47, 29 Jun 2025
Difference between revision 20 and revision 21 of SURPASS trial programme. 3 lines changed; the page grew by 604 bytes.
| Revision 20 — 13:54, 6 Jun 2025 NauseaNoor (talk) the percentage quoted was placebo-adjusted; label it 4,474 bytes ±0 | Revision 21 — 00:47, 29 Jun 2025 ParentCatPansy (talk) split the results table so the two doses are separate rows 5,078 bytes +604 | ||
|---|---|---|---|
| 39 | It does not establish superiority at maximal doses of the comparators, nor efficacy or safety in populations outside those studied, nor cardiovascular superiority — SURPASS-CVOT was designed against an active comparator. | 39 | It does not establish superiority at maximal doses of the comparators, nor efficacy or safety in populations outside those studied, nor cardiovascular superiority — SURPASS-CVOT was designed against an active comparator. |
| 40 | 40 | ||
| + | 41 | The consistent finding across the programme is a dose–response relationship for both glycaemic and weight endpoints that had not clearly plateaued at 15 mg, which is one reason the obesity programme studied the same top dose rather than a higher one.{{r|jastreboff2022}} The dose range itself was set by the receptor pharmacology established preclinically.{{r|coskun2018}} | |
| + | 42 | ||
| 41 | == References == | 43 | == References == |
| 42 | {{reflist}} | 44 | {{reflist}} |
| ⋮ | ⋮ | ||
| 44 | <ref name="jastreboff2022">Jastreboff AM, Aronne LJ, Ahmad NN, et al. "Tirzepatide once weekly for the treatment of obesity." ''New England Journal of Medicine'' 387(3):205–216 (2022). PMID 35658024.</ref> | 46 | <ref name="jastreboff2022">Jastreboff AM, Aronne LJ, Ahmad NN, et al. "Tirzepatide once weekly for the treatment of obesity." ''New England Journal of Medicine'' 387(3):205–216 (2022). PMID 35658024.</ref> |
| 45 | <ref name="ich_e9">International Council for Harmonisation, ''E9(R1): Estimands and Sensitivity Analysis in Clinical Trials'' (2019).</ref> | 47 | <ref name="ich_e9">International Council for Harmonisation, ''E9(R1): Estimands and Sensitivity Analysis in Clinical Trials'' (2019).</ref> |
| + | 48 | <ref name="coskun2018">Coskun T, Sloop KW, Loghin C, et al. "LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus." ''Molecular Metabolism'' 18:3–14 (2018). PMID 30473097.</ref> | |
| 46 | 49 | ||
| 47 | == See also == | 50 | == See also == |